knowledge -WSS

knowledge

author：Wikipedia 2025-09-02 11:37:11 - browse：9

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Biotech reporter’s notebook: A sunnier mood at JPM 2024

WSS

As JPM 2024 winds down, some health tech firms project optimism

Private equity could exacerbate cardiology's overuse problem, experts fear

Acelyrin, a rare IPO success, stumbles in its first big test

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

New menopause drug shows promise in relief for hot flashes

How I ended up pumping milk in a bathroom stall at JPM 2024

focus

knowledge

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Duchenne breakthrough therapy leaves behind pioneering families

Telehealth for opioid use disorder is lifesaving

Affirmative action in medical school literally saved lives

DeSantis can now import cheaper drugs. But will Biden get credit?

Apple is now the first public company to be valued at $3 trillion

Idaho abortion case may prompt more restrictions in other states

23andMe had bad news about my health. I wish a person had delivered it

The SUPPORT Act is critical to fighting the opioid crisis

Wikipedia

New menopause drug shows promise in relief for hot flashes

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Risky weight loss products often used by teens globally, per study

How to make the FDA’s new prescription one

New Covid vaccine is recommended for everyone 6 months or older

Readout LOUD podcast: live from JPM 2024

hotspot

hotspot

hotspot

knowledge